Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.46 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 5/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | TDP2 | O95551 | 1/20 | 0.41 |
| ▸ | BCL2 | P10415 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24378152 | 0.90 | KMT2A (0.47) | HSD17B10CYP4F2CYP4A11KMT2AHPGD | |
| SCHEMBL7817820 | 0.87 | HSD17B10 (0.60) | HSD17B10CYP4F2CYP4A11KMT2AHPGD | |
| Hydrochloric Acid SCHEMBL11562060 | 0.86 | HSD17B10 (0.59) | HSD17B10CYP4F2CYP4A11KMT2AHPGD | |
| SCHEMBL24378020 | 0.86 | KMT2A (0.47) | HSD17B10KMT2AHPGDCYP1A2CYP3A4 | |
| SCHEMBL29527171 | 0.85 | POLB (0.55) | HSD17B10CYP4F2CYP4A11KMT2AHPGD | |
| SCHEMBL13675536 | 0.85 | HSD17B10 (0.46) | HSD17B10CYP4F2CYP4A11KMT2AHPGD | |
| SCHEMBL7819909 | 0.85 | HSD17B10 (0.46) | HSD17B10CYP4F2CYP4A11KMT2AHPGD | |
| SCHEMBL3353094 | 0.85 | POLB (0.55) | HSD17B10CYP4F2CYP4A11KMT2AHPGD | |
| SCHEMBL23420329 | 0.84 | HSD17B10 (0.46) | HSD17B10CYP4F2CYP4A11KMT2AHPGD | |
| Hydrochloric Acid SCHEMBL11561609 | 0.84 | HSD17B10 (0.46) | HSD17B10CYP4F2CYP4A11KMT2AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230399304-A1 | COVALENT INHIBITORS OF CREATINE KINASE (CK) AND USES THEREOF FOR TREATING AND PREVENTING CANCER | DANA-FARBER CANCER INSTITUTE, INC. | 2023-12-14 | — | — | US | disclosed |
| US-20230399304-A1 | COVALENT INHIBITORS OF CREATINE KINASE (CK) AND USES THEREOF FOR TREATING AND PREVENTING CANCER | DANA-FARBER CANCER INSTITUTE, INC. | 2023-12-14 | — | — | US | disclosed |
| WO-2022087433-A1 | COVALENT INHIBITORS OF CREATINE KINASE (CK) AND USES THEREOF FOR TREATING AND PREVENTING CANCER | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-04-28 | — | — | WO | disclosed |
| EP-1996563-B1 | HETEROBICYCLIC SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF DIABETES | HOFFMANN LA ROCHE (CH) | 2012-03-21 | — | — | EP | disclosed |
| US-8030308-B2 | Bicyclic sulfonamide derivatives which are L-CPT 1 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2011-10-04 | — | — | US | disclosed |
| US-20110046112-A1 | NOVEL BICYCLIC SULFONAMIDE DERIVATIVES WHICH ARE L-CPT1 INHIBITORS | ACKERMANN JEAN | 2011-02-24 | — | — | US | disclosed |
| US-7879845-B2 | Liver carnitine-dependent palmitoyltransferase (L-CPT1) inhibitors such as 4-{[4-(5-Chloro-2-methoxy-benzenesulfonyl)-3,4-dihydro-2H-benzo[1,4]thiazine-6-carbonyl]-amino}-benzoic acid, used for the treatment of non-insulin dependent diabetes; antidiabetic agents | HOFFMANN-LA ROCHE INC. (US) | 2011-02-01 | — | — | US | disclosed |
| US-20100130484-A1 | NOVEL BICYCLIC SULFONAMIDE DERIVATIVES WHICH ARE L-CPT1 INHIBITORS | ACKERMANN JEAN | 2010-05-27 | — | — | US | disclosed |
| US-7696200-B2 | Bicyclic sulfonamide derivatives which are L-CPT1 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2010-04-13 | — | — | US | disclosed |
| EP-1996563-A1 | HETEROBICYCLIC SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF DIABETES | F.HOFFMANN-LA ROCHE AG (CH) | 2008-12-03 | — | — | EP | disclosed |
| WO-2007093507-A1 | HETEROBICYCLIC SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF DIABETES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-23 | — | — | WO | disclosed |
| US-20070191603-A1 | Novel bicyclic sulfonamide derivatives which are L-CPT1 inhibitors | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046112-A1 | NOVEL BICYCLIC SULFONAMIDE DERIVATIVES WHICH ARE L-CPT1 INHIBITORS | CPT1A, CPT1B, CPT2 | HSD17B10 294/4885CYP4F2 446/4885CYP4A11 459/4885 |
| US-20100130484-A1 | NOVEL BICYCLIC SULFONAMIDE DERIVATIVES WHICH ARE L-CPT1 INHIBITORS | CPT1A, CPT1B, CPT2 | HSD17B10 294/4885CYP4F2 446/4885CYP4A11 459/4885 |
| US-20070191603-A1 | Novel bicyclic sulfonamide derivatives which are L-CPT1 inhibitors | CPT1A, CPT1B, CPT2 | HSD17B10 294/4885CYP4F2 446/4885CYP4A11 459/4885 |
| US-20230399304-A1 | COVALENT INHIBITORS OF CREATINE KINASE (CK) AND USES THEREOF FOR TREATING AND PREVENTING CANCER | CKMT1A; CKMT1B, PHKG1, PCK1 | HSD17B10 1077/4885CYP4F2 2245/4885CYP4A11 3363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.